Page last updated: 2024-11-13

(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methyl methanesulfonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

The chemical name you provided, **(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methyl methanesulfonate**, refers to a compound that is likely a **potent and selective antagonist** for the **neuropeptide Y (NPY) Y1 receptor**.

Here's why this compound is important for research:

* **NPY and its receptors:** NPY is a neuropeptide found in the brain and peripheral tissues. It plays a crucial role in regulating various physiological functions, including appetite, stress response, and cardiovascular function. It exerts its effects through a family of G protein-coupled receptors, of which Y1 is one of the most prominent.
* **Y1 receptor antagonism:** Blocking the Y1 receptor can have therapeutic potential in several conditions, including:
* **Obesity:** Y1 receptors are involved in appetite regulation and their antagonism could lead to reduced food intake and weight loss.
* **Anxiety and depression:** NPY plays a role in stress response and anxiety, and Y1 antagonists might have anxiolytic and antidepressant properties.
* **Cardiovascular diseases:** Y1 receptor activation contributes to vasoconstriction and hypertension, and Y1 antagonists could potentially lower blood pressure and improve cardiovascular health.
* **Importance of (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methyl methanesulfonate:** This specific compound, due to its chemical structure, is likely designed to be a potent and selective antagonist of the Y1 receptor. This selectivity is important because it can minimize side effects associated with targeting other NPY receptors.
* **Research applications:** This compound is likely being investigated in preclinical studies to assess its efficacy, safety, and potential therapeutic use in various conditions where Y1 receptor antagonism is considered a promising strategy.

**However, please note that this information is based on the compound's structure and its possible function as a Y1 antagonist. Specific details about its research applications, pharmacological profile, and clinical development are not readily available from the given chemical name.**

To find more detailed information, you would need to consult scientific literature, databases, or contact researchers working in this specific field.

(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methyl methanesulfonate: a GPR119 agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID57930198
SCHEMBL ID388551
MeSH IDM0593637

Synonyms (10)

Synonym
QJWSXYVTYPMVON-UHFFFAOYSA-N
{1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}methyl methanesulfonate
(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methyl methanesulfonate
1032825-19-6
SCHEMBL388551
{1-[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-4-yl}methyl methanesulfonate
DTXSID50728303
(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methylmethanesulfonate
[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]methyl methanesulfonate
A927037

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Sitagliptin increased active GLP-1, but caused a profound suppression of total PYY, GLP-1, and GIP when dosed alone or with GSK263."( Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]